BioSpace News Archive

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced the closing of its previously announced public offering of 16,667,000 shares of common stock, at a public offering price of $0.30 per share.

Immunome, Inc. announced the closing of its underwritten public offering of 10,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,500,000 shares, at a price to the public of $20.00 per share.

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 131,688 shares of its common stock to four newly hired employees, consisting of inducement stock options to purchase an aggregate of 75,250 shares of common stock and inducement restricted stock units, covering an aggregate of 56,438 shares of its common stock.

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced that it was notified by the World Trade Center Health Program that, due to a clerical error, the EsoGuard® Esophageal DNA test was incorrectly listed as a covered benefit.

AstraZeneca’s TAGRISSO® with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.